Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
Sumitomo Corporation passed a resolution to revise the stock-based remuneration system of the Company in the Board of Directors meeting as follows. This revision will take effect subject to. | March 31, 2023